Skip to content

Effects of Yoga and Relaxation on Stress and Quality of Life

Effects of Yoga and Relaxation on Stress and Quality of Life - a Three-armed Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04039074
Enrollment
102
Registered
2019-07-31
Start date
2019-07-29
Completion date
2021-06-30
Last updated
2022-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress, Psychological

Keywords

Yoga, Meditation, Progressive muscle relaxation, Stress, Education

Brief summary

The aim of this study is to measure the effects of three stress reduction methods on patients with stress and stress associated complaints.

Interventions

BEHAVIORALIntegrative Yoga

A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice.

BEHAVIORALIyengar Yoga

A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).

BEHAVIORALMindfulness

A 12-week mindfulness intervention designed for the healthy handling of stress.

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

\- stress with at least 4 of 10 points on the Numeric Analogue Scale (NAS) at least 1 month and at least 3 of the following 8 stress symptoms: sleep disorder, inappetence or increased appetite, shoulder neck tension/back pain, tension headache, concentration disorder, exhaustion, nervousness/irritability, stress-associated digestive problems

Exclusion criteria

* serious acute or chronic diseases * pregnancy or lactation * known serious mental illness * immobility or restriction for gymnastics exercises due to orthopaedic, neurological or other medical cause * participation in another study

Design outcomes

Primary

MeasureTime frameDescription
Stress questionnaire (Cohen Perceived Stress Scale, CPSS)Date of inclusion (baseline), after 12 weeks, after 24 weeksChange from Baseline in the CPSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.

Secondary

MeasureTime frameDescription
Heart Rate Variability (HRV)Date of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Faros 180 (chest)
Medical Outcomes Study Short Form Quality of Life (MOS SF-36)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-100, higher score meaning a better outcome
Hospital Anxiety and Depression Scale (HADS)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-42, lower score meaning a better outcome
Zerssen symptom list (B-LR and B-LR')Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 20-80, higher score meaning a better outcome
International Physical Activity Questionnaire (IPAQ)Date of inclusion (baseline), after 12 weeks, after 24 weeksMET minutes represent the amount of energy expended carrying out physical activity. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS.
Maslach Burnout Inventory (MBI)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-96, higher score meaning a better outcome
Mindfulness (Freiburger Fragebogen zur Achtsamkeit, FFA)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-56, higher score meaning a better outcome
Aspects of Spirituality (ASP)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-112, higher score meaning a better outcome
Self-RegulationDate of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 16-96, higher score meaning a better outcome
Dietary Behaviour assessed by Food Frequency Questionaire (Gesundheit Erwachsener in Deutschland, DEGS)Date of inclusion (baseline), after 12 weeks, after 24 weeksQuantitative description of nutritional habits
Medication intakeDate of inclusion (baseline), after 12 weeks, after 24 weeksName of medication and dosage
Multidimensional Assessment of Interoceptive Awareness (MAIA)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-160, higher score meaning a better outcome
Trauma symptoms (Posttraumatic Checklist, PCL-5)Date of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-80, higher score meaning a better outcome
Mysticism Scale Short FormDate of inclusion (baseline), after 12 weeks, after 24 weeksAssessing full scale, range 0-32, higher score meaning a better outcome
Numerical Analog ScalesDate of inclusion (baseline), after 12 weeks, after 24 weeksAssessing stress, back pain, headache, shoulder/neck tension, sleep quality, exhaustion, nervousness, digestive complaints, mood on 0-11 points each.
Expectation questionsDate of inclusion (baseline)For intervention 1, intervention 2 and intervention 3 on a 6-point likert scale from 1 (very strong) to 6 (nothing at all)
Bio-electrical Impedance Analysis (BIA)Date of inclusion (baseline), after 12 weeks, after 24 weeksEstimation of the body composition via bio-electrical impedance analysis (muscle mass in kg)
Sociodemographic MeasurementsDate of inclusion (baseline)Age, gender, education level, household income, employment status, marital status, language spoken, complete family history, current and previous illness and co-morbidities, and current medications
Behavioral questions: alcohol consumptionDate of inclusion (baseline), after 12 weeks, after 24 weeksNumber of alcoholic beverages on average per week in the last month
Behavioral questions: relaxationDate of inclusion (baseline), after 12 weeks, after 24 weeksRelaxation behavior on average per week in the last month in minutes
Behavioral questions: cigarettesDate of inclusion (baseline), after 12 weeks, after 24 weeksNumber of cigarettes on average per week in the last month in minutes
Electrodermal Activity (Galvanic Skin Response)Date of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Blood Volume PulseDate of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Respiration RateDate of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Interbeat Interval (IBI)Date of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Heart Rate (HR)Date of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Faros 180 (chest), Biovotion Everion
Skin TemperatureDate of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Blood OxygenizationDate of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Body weight (kg)Date of inclusion (baseline), after 12 weeks, after 24 weeks24h measuring by Biovotion Everion device
Body Mass Index (kg/m2)Date of inclusion (baseline), after 12 weeks, after 24 weeks
Waist circumference (cm)Date of inclusion (baseline), after 12 weeks, after 24 weeks
Evaluation questionsAfter 12 weeks, after 24 weeksFor intervention 1, intervention 2 and intervention 3 on a 6-point likert scale from 1 (very strong) to 6 (nothing at all)

Other

MeasureTime frameDescription
Qualitative interviews in focus groups interviews12 weeks after inclusionQualitative assessment will be carried out in 45-minute focus group interviews in 12 (randomized selected) patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026